Stocks analysis

ABBV vs ABNB Stock Comparison

Scores Breakdown

Metric ABBV ABNB
📈 Growth 15/30 14/30
💰 Profitability 16/20 18/20
🏦 Financial Health 12/20 15/20
💵 Valuation 12/20 10/20
⚠️ Risk (lower is better) 6/10 6/10
Overall Score 59/100 61/100

Side-by-Side Summaries

ABBV Analysis ABNB Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

8 quarters show revenue starting at 2.748B (2024 Q2) and ending at 2.678B (2026 Q1), a small decline; a peak of 4.095B in 2025 Q3 underscores episodic demand strength. Net income rose from 461M in 2024 Q2 to a high of 1.374B in 2025 Q3, then declined to 160M in 2026 Q1, highlighting volatility with a mid-period peak.

💰 Margins & Cash Flow

Gross margin remains elevated, with gross_profit relative to revenue above ~75-85%; for 2026 Q1, gross_profit 2.097B vs. revenue 2.678B implies ~78% margin. Operating cash flow has been positive in most quarters, notably 1.708B in 2026 Q1 and 1.356B in 2025 Q3, while investing activities are generally negative and financing moves swing cash flow.

🛡️ Balance Sheet & Liquidity

Balance sheet shows resilient assets of about $26.8B with current assets around $23.6B and equity near $7.64B in 2026 Q1; debt includes $2.48B long-term, supporting liquidity. This mix supports liquidity even in travel-cycle downturns, though elevated liabilities vs. equity suggest moderate leverage.

⚠️ Key Drivers & Risks

  • Drivers: travel demand rebound, Airbnb network effects
  • Risks: travel volatility, regulatory/competitive pressures, valuation sensitivity to growth deceleration